The Wnt Gatekeeper SFRP4 Modulates EMT, Cell Migration and Downstream Wnt Signalling in Serous Ovarian Cancer Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Ford, Caroline E ^a   Jary, Eve ^a   Ma, Sean Si Qian ^a   Nixdorf, Sheri ^a   Heinzelmann Schwarz, Viola A ^a   Ward, Robyn L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; COLLAGEN; CYCLIN D1; FIBRONECTIN; MYC PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 4; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VIMENTIN;

ARTICLE; AXIN2 GENE; CANCER CELL; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; CYCLIND1 GENE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; ONCOGENE MYC; OVARY CARCINOMA; PROTEIN EXPRESSION; WNT SIGNALING PATHWAY;

BETA CATENIN; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENETIC VECTORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECOMBINANT PROTEINS; TRANSFECTION; WNT SIGNALING PATHWAY;

PYRONIA TITHONUS;

EID: 84872221731     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054362     Document Type: Article

References (40)

1. Banerjee S, Kaye S, (2011) The role of targeted therapy in ovarian cancer. Eur J Cancer 47Suppl 3: S116-130.
2. Bovicelli A, D'Andrilli G, Giordano A, (2011) New players in ovarian cancer. J Cell Physiol 226: 2500-2504.
3. Berns EM, Bowtell DD, (2012) The changing view of high-grade serous ovarian cancer. Cancer Res 72: 2701-2704.
4. Bowtell DD, (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10: 803-808.
5. Hiss D, (2012) Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol 2012: 737981.
6. Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA (2012) Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC). J Intern Med.
7. Karst AM, Drapkin R, (2010) Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010: 932371.
8. Dubeau L, (2008) The cell of origin of ovarian epithelial tumours. Lancet Oncol 9: 1191-1197.
9. Barbolina MV, Burkhalter RJ, Stack MS, (2011) Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J 437: 1-12.
10. Schmid S, Bieber M, Zhang F, Zhang M, He B, et al. (2011) Wnt and hedgehog gene pathway expression in serous ovarian cancer. Int J Gynecol Cancer 21: 975-980.
11. Yoshioka S, King ML, Ran S, Okuda H, MacLean JA, 2nd, et al (2012) WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/beta-catenin pathway. Mol Cancer Res 10: 469-482.
12. Chien AJ, Conrad WH, Moon RT, (2009) A Wnt survival guide: from flies to human disease. J Invest Dermatol 129: 1614-1627.
13. Ying Y, Tao Q, (2009) Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics 4: 307-312.
14. Shi Y, He B, You L, Jablons DM, (2007) Roles of secreted frizzled-related proteins in cancer. Acta Pharmacol Sin 28: 1499-1504.
15. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, et al. (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36: 417-422.
16. Jost E, Gezer D, Wilop S, Suzuki H, Herman JG, et al. (2009) Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma. Cancer Lett 281: 24-31.
17. Huang J, Zhang YL, Teng XM, Lin Y, Zheng DL, et al. (2007) Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer 7: 126.
18. Jacob F, Ukegijni K, Nixdorf S, Ford C, Olivier J, et al. (2012) Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients. PLoS One 7: e31885.
19. Nieto MA, (2011) The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 27: 347-376.
20. Thiery JP, Acloque H, Huang RY, Nieto MA, (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
21. Micalizzi DS, Farabaugh SM, Ford HL, (2010) Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 15: 117-134.
22. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
23. Rask K, Nilsson A, Brannstrom M, Carlsson P, Hellberg P, et al. (2003) Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer 89: 1298-1304.
24. Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, et al. (2001) Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci U S A 98: 14973-14978.
25. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, et al. (2002) Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 22: 1184-1193.
26. Hadjihannas MV, Bruckner M, Behrens J, (2010) Conductin/axin2 and Wnt signalling regulates centrosome cohesion. EMBO Rep 11: 317-324.
27. Wu ZQ, Brabletz T, Fearon E, Willis AL, Hu CY, et al. (2012) Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. Proc Natl Acad Sci U S A.
28. Hashiguchi Y, Tsuda H, Inoue T, Nishimura S, Suzuki T, et al. (2004) Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum Pathol 35: 165-175.
29. Karve TM, Li X, Saha T, (2012) BRCA1-mediated signaling pathways in ovarian carcinogenesis. Funct Integr Genomics 12: 63-79.
30. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, et al. (2011) Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 6: e18064.
31. Skirnisdottir IA, Sorbe B, Lindborg K, Seidal T, (2011) Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer 21: 236-244.
32. von Marschall Z, Fisher LW, (2010) Secreted Frizzled-related protein-2 (sFRP2) augments canonical Wnt3a-induced signaling. Biochem Biophys Res Commun 400: 299-304.
33. Mii Y, Taira M, (2011) Secreted Wnt "inhibitors" are not just inhibitors: regulation of extracellular Wnt by secreted Frizzled-related proteins. Dev Growth Differ 53: 911-923.
34. Kawano Y, Kypta R, (2003) Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116: 2627-2634.
35. Horvath LG, Lelliott JE, Kench JG, Lee CS, Williams ED, et al. (2007) Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. Prostate 67: 1081-1090.
36. Carmon KS, Loose DS, (2008) Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells. Mol Cancer Res 6: 1017-1028.
37. Takebe N, Harris PJ, Warren RQ, Ivy SP, (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8: 97-106.
38. Clevers H, Nusse R, (2012) Wnt/beta-Catenin Signaling and Disease. Cell 149: 1192-1205.
39. Veeck J, Dahl E, (2012) Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochim Biophys Acta 1825: 18-28.
40. Kogan Y, Halevi-Tobias KE, Hochman G, Baczmanska AK, Leyns L, et al. (2012) A new validated mathematical model of the Wnt signalling pathway predicts effective combinational therapy by sFRP and Dkk. Biochem J 444: 115-125.